Indaptus Therapeutics Inc
Change company Symbol lookup
Select an option...
INDP Indaptus Therapeutics Inc
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc
LZM Lifezone Metals Ltd
LMRMF Lomiko Metals Inc
SOXL Direxion Daily Semiconductor Bull 3X Shares
OXSQ Oxford Square Capital Corp
BAER Bridger Aerospace Group Holdings Inc
CMRA Comera Life Sciences Holdings Inc

Health Care : Biotechnology |
Company profile

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

Day's Change
-0.25 (-9.23%)
B/A Size
Day's High
Day's Low

Today's volume of 27,213 shares is on pace to be much lighter than INDP's 10-day average volume of 40,136 shares.


Odeon initiates coverage of 'stabilized' PacWest with hold rating

8:57 am ET June 8, 2023 (MarketWatch)

Odeon Capital analyst Richard Bove on Thursday initiated coverage of PacWest Bancorp (PACW) with a hold rating. Although the company remains in a high-risk situation, "fears of this company disappearing may have dissipated so that speculators might wish to continue to hold the stock," Bove said in a research note. PacWest has stabilized at the moment by selling some assets and buying brokered deposits a rates up to 5.35%, Bove said. The bank may manage to find a buyer for all or part of its business, after it announced recently it was exploring strategic alternatives. "Assuming that it is not hit with more large deposit outflows, it may succeed in its quest although it is possible that the price offered for the company could be a buy-under," Bove said. PacWest stock was up 2.5% in premarket trades Thursday on top of a 14.4% rally on Wednesday.

-Steve Gelsi

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

June 08, 2023 08:57 ET (12:57 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.